1. Overcoming radioresistance in head and neck squamous cell carcinoma
- Author
-
Michael Bauschard, Isaac L Schmale, David S. Thylur, Uttam K. Sinha, and Vicky Yamamoto
- Subjects
0301 basic medicine ,Oncology ,Radiation-Sensitizing Agents ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Cetuximab ,Radiation Tolerance ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Radioresistance ,medicine ,Humans ,Epidermal growth factor receptor ,biology ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Head and neck cancer ,medicine.disease ,Head and neck squamous-cell carcinoma ,Tumor recurrence ,Radiation therapy ,stomatognathic diseases ,030104 developmental biology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,biology.protein ,Radiosensitizing Agent ,Oral Surgery ,business ,DNA Damage ,medicine.drug - Abstract
Radiation therapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet therapeutic efficacy is hindered by treatment-associated toxicity and tumor recurrence. In comparison to other cancers, innovation has proved challenging, with the epidermal growth factor receptor (EGFR) antibody cetuximab being the only new radiosensitizing agent approved by the FDA in over half a century. This review examines the physiological mechanisms that contribute to radioresistance in HNSCC as well as preclinical and clinical data regarding novel radiosensitizing agents, with an emphasis on those with highest translational promise.
- Published
- 2016
- Full Text
- View/download PDF